中国癌症防治杂志2025，Vol.17Issue(2)：223-229,7.DOI:10.3969/j.issn.1674-5671.2025.02.14
血液系统恶性肿瘤通用型CAR-T细胞治疗进展:GvHD/HvG应对策略
Advances in universal CAR-T cell therapy for hematologic malignancies:strategies to over-come GvHD/HvG
摘要
Abstract
Chimeric antigen receptor(CAR)-T cell therapy has demonstrated remarkable success in the treatment of hematologic ma-lignancies.However,currently approved CAR-T products are predominantly autologous,which face limitations including lengthy manu-facturing processes,high costs,and the variability of product quality,restricting their broad clinical application.Universal CAR-T(UCAR-T)therapy,developed from healthy donor-derived T cells,through ex vivo modification and expansion,offer an"off-the-shelf"product that enable on-demand treatment,thereby overcoming the constraints of autologous CAR-T.Nevertheless,UCAR-T therapy remain challenged at complications including graft-versus-host disease(GvHD)and host-versus-graft reaction(HvG).This review summa-rizes recent progress on strategies to mitigate GvHD and HvG in UCAR-T therapy,including gene editing,non-gene-editing technolo-gies,and optimal cell source selection.关键词
血液系统恶性肿瘤/CAR-T细胞疗法/通用型CAR-T细胞治疗/移植物抗宿主病/宿主抗移植物反应Key words
Hematologic malignancies/CAR-T cell therapy/Universal CAR-T/Graft-versus-host disease/Host-versus-graft reaction分类
医药卫生引用本文复制引用
田晟宇,卢伟祥,梁晓杰,王亮..血液系统恶性肿瘤通用型CAR-T细胞治疗进展:GvHD/HvG应对策略[J].中国癌症防治杂志,2025,17(2):223-229,7.基金项目
国家自然科学基金资助项目(82370188 （）
82170181) （）
